ByTrending Posts
Why Is Eli Lilly’s 2025 Outlook Soaring Despite…
Key Highlights: Strong Sales Growth and Raising GuidanceEli Lilly posted impressive Q2 2025 earnings surpassing estimates, largely on…
Why Could Novartis’ Ianalumab, With Dual Mechanism of B-Cell Depletion and BAFF-R…
Key Highlights: Positive Phase III Results Confirm Efficacy in Sjögren’s DiseaseThe NEPTUNUS-1 (275 patients) and NEPTUNUS-2 (504 patients)…
Can AstraZeneca’s $50 Billion U.S. Investment and Drug…
Key Highlights: Strategic Response to U.S. Pricing PressuresAstraZeneca CEO Pascal Soriot announced proactive proposals for U.S. drug price…
How Google Med-Gemini’s “Basilar Ganglia” AI Hallucination Signal a Wake-Up Call for…
Key Highlights: AI Hallucination: The “Basilar Ganglia” ErrorGoogle’s Med-Gemini suite, designed to summarize health data and generate radiology…
Can XtalPi & DoveTree’s $6 Billion AI Partnership…
Key Highlights: Strategic Overview: Industry’s Largest AI-Pharma CollaborationThis collaboration—one of the biggest in AI-driven drug discovery—combines XtalPi’s robust…
Will CMS’s 2026 WISeR AI Pilot Shift Traditional…
Key Highlights: AI-Powered Prior Authorization: New Model and ScopeCMS’s WISeR (Wasteful and Inappropriate Service Reduction) program introduces AI…
Can Harvard’s FaceAge and Emerging AI Facial Recognition…
Key Highlights: AI Facial Recognition as a Medical BiomarkerDeveloped at Harvard Medical School, the FaceAge algorithm analyzes photos…
How Will BioNTech’s Patent Settlement Impact the Future…
Key Highlights Resolving Patent Litigation and Securing LicensesBioNTech SE and Pfizer reached agreements with CureVac N.V. and GlaxoSmithKline…
Could Eli Lilly’s AI-Driven Innovation Accelerate Biopharma Growth…
Key Highlights Robust Revenue Growth Powered by AI-Driven ProductsIn Q2 2025, Eli Lilly delivered impressive top-line performance with…
Trending Posts
Latest Stories
Could Merck’s USD 349M Collaboration with Variational AI and Its Enki™ Platform Mark a Turning Point for Generative-AI-Designed Small Molecules?
Key Highlights A Strategic Alliance Targeting Hard-to-Crack Therapeutic SpaceVariational AI announced a major collaboration with…
Could Excelsior Sciences’ $95M AI Surge Redefine How Fast Small-Molecule Drugs Reach the Market?
Key Highlights • $95M funding round positions Excelsior to compress multi-month chemistry cycles into weeks,…
Will Novartis’s $12 Billion Avidity Deal Ignite a New Era of AI-Powered RNA Therapeutics and Transform Rare-Disease Innovation?
Key Insights:• Novartis AG acquires Avidity Biosciences for $12 billion (USD 72 per share) —…
Can Eli Lilly and NVIDIA’s AI Supercomputer Redefine Drug Discovery Timelines and Ignite a $40 Billion AI-Biopharma Revolution?
Key Insights:• Lilly builds one of pharma’s first NVIDIA-powered DGX SuperPODs, training AI on millions…
Gallery
